INTRODUCTION
Oral contraceptives have been available for over 20 years and, despite several highly publicised articles on their adverse effects, they have remained one of the most popular methods of contraception throughout the world. A variety of epidemiological studies have linked their use with an increased incidence of venous and arterial thromboembolism, and cigarette smoking has been strongly associated with this increased risk, at least with regard to arterial thrombosis.I Recent interest has focused on the effects of oral contraceptives on blood coagulation factors and platelet function.2 Previous studies have shown an increase in platelet aggregation in women receiving the contraceptive pill.3 '4 Cigarette smoking is also a major factor for the development of cardiovascular disease. It has been suggested that both endothelial and platelet factors are involved in the effect of smoking. Although an effect on endothelial damage has largely been confirmed,5' 6 data dealing with platelet function are conflicting. 7' 8 Since epidemiological studies show an increased risk for women who are smokers and are receiving the contraceptive pill,9 this study was carried out to see if this increased risk could be related to effects on the platelet.
METHODS
Women who were intending to start the contraceptive pill were recruited from a local family planning clinic. Informed consent was obtained from all subjects. Ethical approval had been obtained from the Research Ethical Committee of the The Ulster Medical Journal Queen's University of Belfast. Of the 80 subjects recruited for the study, only 50 completed the protocol. Their ages ranged from 17 to 31 years (mean 22 years). Thirty-five were non-smokers and 15 were smokers (mean consumption 15 cigarettes per day). Patients who were on any other regular medication, had any abnormality of their haematological indices or serum lipids, or who had received an oral contraceptive within the previous six months, were excluded from the study. Blood samples were taken for estimation of platelet aggregation before starting the contraceptive pill and four to six months after treatment. All subjects received a combination of 30pg of ethinyloestradiol in combination with 150-250pg of levonorgestrel or 1-5mg norethisterone.
For measurement of platelet aggregation, 20ml venous blood was obtained and immediately anticoagulated with 3-8 % sodium citrate using nine parts blood and one part citrate by volume. After inversion and gentle mixing this was centrifuged at 200 g for 10 minutes. The platelet -rich plasma was removed with a plastic pipette and diluted with saline to give a platelet concentration of 4 x 108 cells/ml. One ml aliquots of this were pipetted into siliconized cuvettes and placed in the heated block of an aggregometer. When the sample stablilized at 37°C a magnetic stir-bar and the impedence electrode were inserted into the cuvette. The aggregometer and recorder were then brought to zero at the pre -set baseline and calibrated using the integral 5 ohm resistance. The recorder was started immediately after the addition of 10pi of aggregation agent. After four minutes for ADP or seven minutes for adrenaline, the recorder was stopped, the pen deflection measured and the impedence of ohms calculated. These agents were used because they have been the two most commonly employed in similar studies examining platelet aggregation with the contraceptive pill. The aggregating reagents used were supplied by the Sigma Chemical Company and were designed to produce a final concentration of 2 mmol/l in the prepared sample. Comparisons between baseline and 4 -6 months of therapy and between smokers and non-smokers were made using a paired t test. Values are expressed as the mean ± standard deviation of the mean.
RESULTS
Adrenaline failed to induce platelet aggregation in several patients. We therefore excluded those patients who had a response of less than 3 ohms (sensitivity of the method) from further analysis. On 12 and those of the combined contraceptive pill to be on the platelet.
